LABCORP HOLDINGS INC.
At today's price, LABCORP HOLDINGS INC. (LH) is priced for +0.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Labcorp runs two businesses: a vast clinical-diagnostics lab network and a biopharma laboratory-services arm that supports drug-developer trials, giving it both steady testing volume and exposure to pharma research spending. • Growth is steady rather than spectacular, revenue up about 6% in the most recent quarter, and the price embeds only modest expectations, which makes execution and margin the swing factors rather than a high-growth story. • The balance sheet carries meaningful debt, aroun
Is LH overvalued? See what's priced in →
1,002 institutional managers reported holding LH in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 44%. 89 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 3.3M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LH has cut its share count 27.4% over the past five years, spending $4.20B on repurchases. It pays a dividend, and has for 4 years running; the current rate is $2.88 a share annually. Cash returned over the past three years: $670.00M in dividends and $1.80B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at LH over the trailing three years. Absence is a fact about the company, not a signal. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -0.5% | -6.4% |
| 2023-10-31 | +0.6% | +16.4% |
| 2024-02-27 | -5.0% | -6.6% |
| 2024-05-01 | -4.6% | +1.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LH's latest 8-K filings: 2026-07-10 (items 7.01, 9.01); 2026-06-30 (items 7.01, 9.01); 2026-05-27 (items 7.01, 9.01); 2026-05-26 (items 5.07); 2026-04-30 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.